Liquid Biopsy Market Size, Share, By Offering (Instruments, Reagents & Kits, and software and services), Biomarker (Circulating Tumor (CTC), Circulating Nucleic Acids, Exosomes, Circulating Biomarkers and Others), Technology (Next-generation Sequencing (NGS), and Polymerase Chain Reaction (PCR), Indication (Lung Cancer, Breast Cancer, Prostate Cancer and Others), Sample Type (Blood, Urine, Saliva, and Others), Clinical Applications (Diagnosis & Screening, Treatment Selection, Drug Resistance, Prognosis, and Others), End-user (Hospitals & Laboratories, Specialty Clinics, Academic & Research Centers, and Others), and Region - Trends, Analysis, and Forecast till 2035

• By 2035, the target market is expected to grow at USD 93.0 Billion.
• In 2024, the Liquid Biopsy Market size accounted for USD 9.63 Billion.
• The market is expanding at a CAGR of 25.6%.

Liquid biopsy is a non-invasive blood, urine, and other bodily fluid test that can help to detect cancer, monitor its progression, and plan a treatment for cancer therapy. Cancer is a major disease that is burdened across the globe and increasing day by day due to factors, such as air pollution, biological risk, and others. The expanding acceptance of artificial intelligence in liquid biopsy technology drives the liquid biopsy market growth. The increasing demand for cancer screening tests, the high focus of manufacturers on developing new techniques, and the extensive application of these tests also boost the market expansion.

For instance, in October 2024, BD Company launched its new line of high-throughout, robotics-compatible reagent kits which is designed to ensure consistency and efficiency in single-cell research, and the aim of this kit is to accelerate the generation of material for genetic sequencing.

Key Takeaways:

• North America hold the largest position in the liquid biopsy market due to high cancer prevalence and advanced healthcare infrastructure, particularly in U.S. and Canada.
• By biomarker, the circulating tumor cells dominates target market owing to tumor cells found in the bloodstream and circulates throughout the body allowing for personalized treatment plans.

Key Drivers of Target Market:

Advancement in Technologies Drives the Market Growth

Liquid biopsy technology can be advanced in several ways to develop new methods and technologies to detect cancer and tumor tissues, it is also used to examine bodily fluids such as blood, urine and others. New technologies such as cancer screening, therapeutic selection, drug trial and monitoring. These technologies improved detection and monitor cancer to guide treatment steps.

• For Instance, in September 2024, ArcanaBio announced its selection for funding by Denmark’s BioInnovation Institute to revolutionize healthcare with new Ultra-rapid liquid biopsy technology. This new technology aimed to build new capability to provide powerful real-time and predictive insights into health status, disease progression and epidemiology.

Integration of AI into Liquid Biopsy Samples is Expected to Drive Market Expansion

Artificial intelligence (AI) enhances the accuracy of cellular data extracted from the liquid biopsy samples. Through advanced algorithms and machine learning, AI can analyze vast amounts of genetic, proteomic, and cellular data extracted from liquid biopsy samples. AI is catalyzing the expansion of liquid biopsy application in healthcare and improve patient outcomes, resulting to drive liquid biopsy market.

• For Instance, in January 2025, Viz.ai and Guardant Health (GH) announced collaboration to improve lung cancer through the integration of AI and genomic insights. This collaboration is focused on timely biomarker testing by using Guardant 360 CDx liquid biopsy. This initiative is aimed to tackle delays in diagnosis, testing, and treatment selection.

Restraints:

High Costs of Tests Disrupt the Target Market Growth

The technologies, such as polymerase chain reaction and next-generation sequencing has significant role in clinical applications, such as cancer detection. However, the costs of these techniques remain high, which is not affordable to every patient, thus it will affect the target market growth.

• Counterbalance Statement: To reduce cost of liquid biopsy test, implement more automated testing process, which significantly reduce manual efforts and allow faster and more comprehensive testing by lowering overall costs for the test.

Opportunities & Market Trends:

Expansion in Cancer Diagnostics Enhances Target Market Opportunity

Liquid biopsy has various advantages over traditional biopsy methods as liquid biopsy is non-invasive, help for personalize treatment, and provides real-time information. It helps to detect and monitor cancer in several body fluids and also tumor tissue.  Also, it detects early stage of cancer and examine disease progression for various types of cancers, such as prostate cancer, lung cancer, and breast cancer. Liquid biopsy is used for diagnostics and screening and also gives ancestral history of patients resulting to drive liquid biopsy market growth.

The liquid biopsy market is segmented into offering, biomarker, technology, indication, sample type clinical application, end-user, and region.

Offering:

By offering, the liquid biopsy market is segmented into instruments, reagents & kits, software and services. Software & service is dominant over other segments due to the increasing number of chronic diseases, such as cancer and tumor disorder. Thus, there is high demand for early detection of diagnosis and treatment, further propelling the target market growth.

Biomarker:

Biomarker is segmented into circulating tumor (CTC), circulating nucleic acids, exosomes, circulating biomarkers, and others. The circulating tumor (CTC) segment holds the largest liquid biopsy market share. As circulating tumor cells from the primary tumor are found into the bloodstream and circulate in the body and through blood sampling these can be used for detection of cancer and its progression allowing for personalized treatment strategies, drives the segment’s expansion in the market.

Technology:

Liquid biopsy market by technology is classified into next-generation sequencing and polymerase chain reaction. Next-generation techniques dominate over other segments in technology due to the demand for the non-invasive techniques for the analysis of mutation and alteration in DNA in circulating tumor cells.

• For instance, in January 2023, Agilent announced the acquisition of Avida Biomed, to develop high-performance of target enrichment workflows of next-generation sequencing for cancer research. This acquisition is aimed to enable simultaneous genomic and DNA methylation profiling from a single sample without reducing sensitivity and specificity of NGS workflow.

 Indication:

By indication liquid biopsy is divided into lung cancer, breast cancer, prostate cancer and others. The lung cancer segment is expected to dominate the liquid biopsy market owing to the rising prevalence of lung cancer globally and increasing demand for early detection by using liquid biopsy.

• For instance, in November 2024, Biofidelity has introduced its Aspyre Lung reagents molecular diagnostic assay, it helps to identify biomarker associated with non-small cell lung carcinoma. This assay is also detected biomarkers associated with DNA and RNA from tissue and blood samples.

Sample Type:

Samples for the liquid biopsy separated into blood, urine, saliva, and other. The blood segment is dominant over other types of samples due to blood containing biomarkers, such as circulating tumor cells and circulating tumor DNA. These biomarkers can be easily identified after collecting blood samples from the patient and they also give genetic information of patient.

Clinical Application

By clinical application, the market is divided into diagnosis & screening, treatment selection, drug resistance, prognosis, and others. The treatment selection segment holds a dominant position in the market as it is the first step after diagnosis and screening of cancer disorder.

End-user:

By end-user, the liquid biopsy market is categorized into hospitals & laboratories, specialty clinics, academic& research centers, and others. The academic & research centers are expected to lead the liquid biopsy market based on end-user because they are primarily focused on conducting research. It involves the study of molecular and genetic alternation in cancer screening step.

 Region:

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: It is the dominant region in the liquid biopsy market due to advanced healthcare infrastructure, increasing cancer prevalence, and adoption of innovative liquid biopsy technologies in this region, leading to growth of liquid biopsy market in upcoming years.

• For instance, in April 2024, the Royal Marsden and Guardant Health collaborate to develop a cutting-edge liquid biopsy test aimed to improve the treatment and outcomes for lung cancer patients. The circulating tumor DNA (ctDNA) technology used by Marsden360 test, which is designed to detect small qualities of ctDNA released into the bloodstream by cancer cells.

Asia Pacific: This is the fastest growing region in the target market due to the rising development in the life science field, along with the development of advanced technologies, and increasing awareness regarding advanced diagnostic technology.

Liquid Biopsy Market Report Scope:

Attribute	Details
Market Size 2025	USD 11.7 Billion
Projected Market Size 2035	USD 93.0 Billion
CAGR Growth Rate	25.6% (2025-2035)
Base year for estimation	2024
Forecast period	2025 – 2035
Market representation	Revenue in USD Billion & CAGR from 2025 to 2035
Regional scope	North America - U.S. and Canada Europe – Germany, U.K., France, Russia, Italy, Spain, Netherlands, and Rest of Europe Asia Pacific – China, India, Japan, Australia Indonesia Malaysia, South Korea, and Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, and Rest of Latin America Middle East & Africa – GCC, Israel, South Africa, and Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segmentation:

By Offering:

• Instruments
• Reagents & Kits
• Software
• Services

By Biomarker:

• Circulating Tumor (CTC)
• Circulating Nucleic Acids
• Exosomes
• Circulating Biomarkers
• Others

By Technology:

• Next-generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)

By Indication:

• Lung cancer
• Breast cancer
• Prostate cancer
• Others

By Sample Type:

• Blood
• Urine
• Saliva
• Others

By Clinical Application:

• Diagnosis & Screening
• Treatment Selection
• Drug Resistance
• Prognosis
• Others

By End-user:

• Hospitals & Laboratories
• Specialty Clinics
• Academic& Research Centers
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the liquid biopsy market include ANGLE plc, Thermo Fisher Scientific, and others.  Liquid biopsy companies launching new innovations to detect early cancer stage in patients. The expanding acceptance of artificial intelligence in liquid biopsy technology to maintain dominance in the market.

List of Key Players in the Market:

• ANGLE plc
• Thermo Fisher Scientific, Inc.
• Guardant Health
•  Personalis, Inc
• Bio-Rad Laboratories, Inc
• Illumina, Inc.
• Menarini Silicon Biosystems
• Myriad Genetics, Inc.
• Lucence Health Inc.
• Freenome Holdings, Inc
• Natera, Inc
• F. Hoffmann-La Roche Ltd.
• QIAGEN
• Epigenomics AG

• In October 2024, GeneCentric Therapeutics has launched the EXpressCTSM (Expression Signatures through Circulating Tumor Signals). The aim of this liquid biopsy technology is to bring RNA-based gene expression to analyze blood and urine samples. EXpressCT can analyze RNA expression and epigenetic changes in cell-free DNA samples. This biomarker is targeted toward HER2 and antibody-drug conjugates.
• In November 2023, Illumina Inc., announced a new generation of liquid biopsy assay to enable comprehensive genomic profiling of solid tumors. The new TruSight Oncology 500 ctDNA v2 is a research assay that enable noninvasive comprehensive genomic profiling of circulating tumor from blood to complement tissue-based testing.

Analyst View:

Liquid biopsy gives early detection of cancer in human’s body, which is advanced technology from the traditional biopsy methods. Liquid biopsy detects biomarker circulating in the blood stream and also helps to doctor to recognize tumor related genetic disorders and detects. The rising prevalence of cancer, increasing research and development activities for liquid biopsy is expected to drive target market growth in coming years.

More Related Reports

Zero Liquid Discharge Market
Liquid Feed Supplements Market
Liquid Crystal Polymer (LCP) Market
E-Liquids Market
Biopsy Devices Market

Company Name	Thermo Fisher Scientific
Headquarter	Waltham, Massachusetts, U.S.
CEO	Marc N. Casper
Employee Count (2024)	122,000 Employees